| Title | ACK1 and BRK non-receptor tyrosine kinase deficiencies are associated with familial systemic lupus and involved in efferocytosis. |
| Publication Type | Journal Article |
| Year of Publication | 2024 |
| Authors | Guillet S, Lazarov T, Jordan N, Boisson B, Tello M, Craddock B, Zhou T, Nishi C, Bareja R, Yang H, Rieux-Laucat F, Lorenzo RIrene Freg, Dyall SD, Isenberg D, D'Cruz D, Lachmann N, Elemento O, Viale A, Socci ND, Abel L, Nagata S, Huse M, W Miller T, Casanova J-L, Geissmann F |
| Journal | medRxiv |
| Date Published | 2024 Jun 05 |
| Abstract | Systemic Lupus Erythematosus (SLE) is an autoimmune disease, the pathophysiology and genetic basis of which are incompletely understood. Using a forward genetic screen in multiplex families with systemic lupus erythematosus (SLE) we identified an association between SLE and compound heterozygous deleterious variants in the non-receptor tyrosine kinases (NRTKs) ACK1 and BRK. Experimental blockade of ACK1 or BRK increased circulating autoantibodies in mice and exacerbated glomerular IgG deposits in an SLE mouse model. Mechanistically, non-receptor tyrosine kinases (NRTKs) regulate activation, migration, and proliferation of immune cells. We found that the patients' ACK1 and BRK variants impair efferocytosis, the MERTK-mediated anti-inflammatory response to apoptotic cells, in human induced Pluripotent Stem Cell (hiPSC)-derived macrophages, which may contribute to SLE pathogenesis. Overall, our data suggest that ACK1 and BRK deficiencies are associated with human SLE and impair efferocytosis in macrophages. |
| DOI | 10.1101/2024.02.15.24302255 |
| Alternate Journal | medRxiv |
| PubMed ID | 38883731 |
| PubMed Central ID | PMC11177913 |
| Grant List | R01 AI124349 / AI / NIAID NIH HHS / United States R01 AI130345 / AI / NIAID NIH HHS / United States R01 CA058530 / CA / NCI NIH HHS / United States R01 AI087644 / AI / NIAID NIH HHS / United States P30 CA008748 / CA / NCI NIH HHS / United States |
